News Search

Category: School of Medicine

PCI and PACT Host AI Event for Philly Tech Week 

PCI and the Philadelphia Alliance for Capital and Technologies (PACT) jointly presented a recent event called “AI Nexus: Shaping Tomorrow’s Intelligence."

A Rare Patient Mutation May Help Lead to More Effective Treatments for Genetic Bone Disease 

Davis' relatively benign symptomology is attributed to low levels of the inflammatory protein MMP-9, which seems to prevent the characteristic abnormal bone formation.

Penn Researchers Create Novel mRNA-based Avian Flu Vaccine 

Penn Medicine researchers have developed an mRNA vaccine for the H5N1 avian flu using techniques similar to those enabling mRNA-based COVID-19 vaccines.

EU Approves Expanded Use of Sobi’s Aspaveli® for Rare Blood Disorder 

The European Commission has approved Sobi's drug Aspaveli® (pegcetacoplan) for broader use in adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder.

Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, Appoints Eugene P. Kennedy as Chief Medical Officer  

Carisma announced the dosing of its first patient in its Phase 1 trial for CT-0525, an innovative CAR-Monocyte therapy targeting HER2-overexpressing solid tumors.

Verismo Therapeutics Receives FDA Clearance for Phase I Trial of its CAR-T Therapy 

Penn spinout Verismo Therapeutics has received FDA clearance for a Phase I trial of its CAR-T therapy, SynKIR-310.

iEcure Receives Three FDA Designations for its In Vivo Gene Insertion Program 

iEcure, a gene-editing company spun out of Penn and co-founded by Dr. Wilson, has received three special designations from the FDA for its new treatment, ECUR-506.

Penn’s CAR-T Treatment Shrank Brain Tumors in Patients in Clinical Trial  

In a new early-stage clinical trial, a Penn-invented CAR-T treatment shrank brain tumors in seven patients with glioblastoma.

Penn Spinout Capstan TherapeuticsRaises $175M in Series B Financing Round

Proceeds from the financing will be used to advance Capstan's lead in vivo chimeric antigen receptor T cell (CAR-T) candidate, CPTX2309, to early clinical proof-of-concept in autoimmune disorders.

iEcure Gains FDA approval to Conduct FirstGene Therapy Treatment  

Utilizing ARCUS, a gene editing tool developed by Precision BioSciences, the therapy aims to provide a lifelong fix for this disease, potentially benefiting thousands of individuals in the US alone.


Skip to content